Pennsylvania Hospital

AVS to Present PULSE™ IVL Clinical Trial Data at 2023 TCT Conference

Retrieved on: 
Wednesday, October 18, 2023
Health, Medical Devices, General Health, Clinical Trials, Research, Science, Cardiology, Practitioner, Peripheral vascular examination, Radiology, PULSE, CRF, Moscone Center, MD, Conference, Artery, IVL, Surgeon, POWER, Pennsylvania Hospital, University, Safety, TCT, University of Pennsylvania Health System, Pain, Patient, Pharmaceutical industry, Medical imaging, AVS

Jon George, MD, a medical advisor to AVS and interventional cardiologist at Pennsylvania Hospital, University of Pennsylvania Health System, will present the abstract during the Peripheral Vascular Intervention Techniques session on Wednesday, Oct. 25, 2023.

Key Points: 
  • Jon George, MD, a medical advisor to AVS and interventional cardiologist at Pennsylvania Hospital, University of Pennsylvania Health System, will present the abstract during the Peripheral Vascular Intervention Techniques session on Wednesday, Oct. 25, 2023.
  • “The POWER PAD I clinical trial results represent groundbreaking data for the future of pulse intravascular lithotripsy,” said Robert Chisena, Ph.D., Chief Technology Officer at AVS.
  • “We are honored to present these new findings at the TCT Conference, the world’s premier conference for cardiovascular data unveiling.”
    The TCT conference has served as a premier showcase of cutting-edge educational content in interventional cardiovascular medicine for over three decades.
  • To learn more about AVS and the PULSE IVL™ System, please visit https://www.avspulse.com .

Medical Simulation Market to grow by USD 1.99 billion from 2022 to 2027, North America to account for 45% of market growth- Technavio

Retrieved on: 
Thursday, September 21, 2023
Approximation error, Telehealth, Medicine, Clinical data management, Life, Teaching, St. Joseph's Hospital, Biotechnology, FREE, USD, Penn Presbyterian Medical Center, Organization, MHealth, Patient, EHR, Physician, Risk, Patient safety, ROW, Growth, Diagnosis, AI, Research, Nursing, Medical device, Retail, Pharmaceutical industry, Hospital, Pennsylvania Hospital, Geography

NEW YORK, Sept. 20, 2023 /PRNewswire/ --The medical simulation market is expected to grow by USD 1.99 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, Sept. 20, 2023 /PRNewswire/ --The medical simulation market is expected to grow by USD 1.99 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of 15.45% during the forecast period, according to Technavio Research.
  • North America is estimated to contribute 45% to the growth of the global market during the forecast period.
  • The presence of major players in the region is expected to drive the growth of the medical simulation market in the region.

PENN MEDICINE TO STOP ACTIVELY PARTICIPATING IN U.S. NEWS & WORLD REPORT "BEST HOSPITALS" RANKINGS

Retrieved on: 
Monday, June 26, 2023
Vaccine, American Hospital Association, Infection, Medical school, Telehealth, University of Pennsylvania Health System, Perelman School of Medicine at the University of Pennsylvania, Hospital of the University of Pennsylvania, University, Education, Centers for Medicare & Medicaid Services, AUC, U.S. News & World Report Best Hospitals Rankings, Hospital, COVID-19, Raymond, Cancer, Biomedical Research, Roll, Research, Medicine, We, Element, Penn Medicine Princeton Medical Center, Penn, U.S. News & World Report, Penn Presbyterian Medical Center, Bangladesh Technical Education Board, Messenger, Medicare, CAR, NYU Annual Survey of American Law, Home, Patient, Susquehanna River, Faculty, Penns, Health, News, Pharmaceutical industry, Pennsylvania Hospital, MD

Modern medicine goes far beyond hospital walls. Today's health systems provide primary care along with advanced care--from surgeries to cancer treatment to kidney dialysis--in outpatient facilities, in patients' homes, and through virtual platforms or remote monitoring. Although the Hospitals of the University of Pennsylvania-Penn Presbyterian has been named to the "Best Hospitals" Honor Roll of top 20 hospitals for the past 16 consecutive years and Penn Medicine's regional hospitals are ranked among the best in the health system's service area, its leaders say the rankings represent an outdated view of health care, failing to capture the full breadth of "care everywhere" services.

Key Points: 
  • The U.S. News & World Report "Best Hospitals" rankings are based solely on inpatient hospital care of those insured by Medicare.
  • While U.S. News & World Report may continue to rank Penn Medicine hospitals, the health system will cease active participation in the process or results.
  • Penn Medicine will also discontinue any promotion of its position on the "Honor Roll," specialty rankings, or any other rankings content, and it will stop purchasing the U.S. News & World Report badges required to publicize the rankings.
  • Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Retrieved on: 
Monday, May 8, 2023
Lymphoma, SAB, Rachel Haurwitz, Perelman School of Medicine at the University of Pennsylvania, CRISPR, University, Reindeer, Research, Thomas Jefferson University, Doctor of Philosophy, AOA, Pennsylvania Hospital, CAR, Patient, Chronic lymphocytic leukemia, Health, Pharmaceutical industry, MD

BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies.

Key Points: 
  • BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB).
  • Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies.
  • “Dr.
  • Schuster’s dedication to patient care and cell therapy research and development offers Caribou invaluable perspectives.

3DR Labs welcomes board-certified diagnostic radiologist to Cardiac Center of Excellence

Retrieved on: 
Tuesday, January 10, 2023
Associate, University, National Institutes of Health Clinical Center, Software testing certification board, Case Western Reserve University, Division, University of Pittsburgh Medical Center, American Board of Commissioners for Foreign Missions, Society, The Massachusetts, MD, Magnetic resonance, Massachusetts General Hospital, Hospital, CT, Society of Cardiovascular Computed Tomography, American Board of Radiology, Chief Medical Advisor to the President, MGH, Radiology, HMS, Pennsylvania Hospital, Weatherhead School of Management, MRI, Harvard Medical School, OH, MBA, Labs, Medical imaging, Health

Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.

Key Points: 
  • Louisville, KY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- 3DR Imaging, LLC is pleased to announce the appointment of Brian Ghoshhajra, MD, MBA, to its Cardiac Center of Excellence as its Medical Advisor.
  • Dr. Ghoshhajra is a board-certified Diagnostic Radiologist with advanced training in Cardiovascular Computed Tomography (CT) and Cardiovascular Magnetic Resonance Imaging (MRI).
  • As the Medical Advisor to 3DR’s Cardiac Center of Excellence, Dr. Ghoshhajra’s vast experience in advanced cardiovascular imaging (including CT and MRI) will support 3DR’s ability to deliver the highest quality post processing services in the rapidly expanding advanced cardiac imaging market.
  • “We are incredibly excited to have Dr. Ghoshhajra’s leadership, expertise and capability in our new Cardiac Center of Excellence”, said Dave Levine, Vice President and General Manager, 3DR Labs.

CHOP Researchers Find COVID-19 Vaccination Leads to Higher Antibody Levels than Natural Infection in Both Pregnant People and their Babies

Retrieved on: 
Wednesday, November 9, 2022
Assistant, Diabetes, Hospital, Hypertension, Vaccination, Antibody, Immunoglobulin G, Patient, University, Vaccine, Infection, CHOP, RNA transfection, Obesity, Pregnancy, Philadelphia, DO, COVID-19, MSCE, JAMA Network Open, DOI, Doctor of Philosophy, Children's Hospital of Philadelphia, Mother, Pediatrics, Efficiency, Pennsylvania Hospital, Gestational age, Comparison, Research, Severe acute respiratory syndrome coronavirus 2, Health, Prussia, Time, Microbiology, Child

PHILADELPHIA, Nov. 9, 2022 /PRNewswire/ --Pregnant people who received one of the mRNA COVID-19 vaccines had 10-fold higher antibody concentrations than those who were naturally infected with SARS-CoV-2, a finding that was also observed in their babies, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP) and the University of Pennsylvania. The study, published today in JAMA Network Open, also found that vaccine timing played an important role in maximizing the transfer of antibodies, with antibodies detected as early as 15 days after the first vaccine dose and increasing for several weeks after.

Key Points: 
  • "Given that pregnancy is a risk factor for severe COVID-19, this study suggests pregnant people should prioritize getting vaccinated to protect themselves and their babies."
  • In collaboration with CHOP researchers, his laboratory evaluated cord blood serum from 585 pregnant people who had detectable SARS-CoV-2 antibodies.
  • They found that antibody levels among vaccine recipients were approximately 10-times higher than in people who had been naturally infected.
  • Of those newborns with detectable antibodies, the researchers found that levels were 10-times higher in the vaccinated group than in the naturally infected group.

The Rita and Alex Hillman Foundation Awards $1.5 Million to Nursing-Driven Innovations

Retrieved on: 
Tuesday, October 25, 2022
People, City, Sexual assault, Housing, HIC, Policy, Patient, Home, BIPOC, Partnership, Technology, Homelessness, Rita, University, Pennsylvania State University, Refugee, Public health, Health, Ecosystem, Sane, GLOBE, Nursing, Transitional care, Pharmaceutical industry, Medicine, Hospital, Medicaid, Pennsylvania Hospital

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The Rita and Alex Hillman Foundation (RAHF) today announced $1.5 million in grants to support three bold new programs addressing the health of marginalized populations.

Key Points: 
  • NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The Rita and Alex Hillman Foundation (RAHF) today announced $1.5 million in grants to support three bold new programs addressing the health of marginalized populations.
  • Established in 2014, the Hillman Innovations in Care (HIC) program and Hillman Catalyst Awards were created to spur the development of innovations that could tackle the complex needs of communities that experience discrimination, oppression and indifference.
  • Nursing must play a critical role in creating a more equitable and just healthcare system, said Ahrin Mishan, Executive Director of The Rita and Alex Hillman Foundation.
  • The Rita and Alex Hillman Foundation advances bold, nursing-driven innovations that promote equitable, person-centered, and trustworthy care.

Assure Holdings Performs First Neuromonitoring Case in New Jersey

Retrieved on: 
Friday, October 14, 2022
Joint Commission, News, U.S. Securities and Exchange Commission, St. Joseph's Healthcare Hamilton, Pennsylvania Hospital, Risk, Emory University, Ear, Thomas Jefferson University Hospital, Education, NASDAQ, Medical Society, New Jersey Medical School, Hospital, RWJBarnabas Health, Surgeon, Annual report, Nose, Medical Society of New Jersey, Spine, Form 10-K, Director, Goal, Company, CEO, Neurosurgery, Adult, Quality assurance, Physician, GLOBE, Forward-looking statement, COVID-19, Nervous system

DENVER, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (IONM) and remote neurology services, is pleased to announce that it has performed its first neuromonitoring case in the state of New Jersey.

Key Points: 
  • DENVER, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the Company or Assure) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (IONM) and remote neurology services, is pleased to announce that it has performed its first neuromonitoring case in the state of New Jersey.
  • Assure will be working with Marc J. Levine, M.D., who performs approximately 200 procedures annually.
  • A Clinical Assistant Professor at Rutgers New Jersey Medical School, he also serves as the Director of Orthopedic Spine Surgery at RWJBarnabas Healthcare-Hamilton.
  • Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services.

Rittenhouse Realty Advisors, a Member of GREA, Sells Center City, Philadelphia Portfolio With 22 Units and Commercial Space for $7.9 Million

Retrieved on: 
Tuesday, September 20, 2022
City, Pine Street, GLOBE, Walking, Rittenhouse Square, RRA, Washington Square West, Philadelphia, Thomas Jefferson University Hospital, Sale, Bank, Financial services, Pennsylvania Hospital

PHILADELPHIA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Rittenhouse Realty Advisors, a member of GREA, is pleased to announce the sale of a mixed-use portfolio of properties in the Washington Square West and Rittenhouse Square neighborhoods of Philadelphia.

Key Points: 
  • PHILADELPHIA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Rittenhouse Realty Advisors, a member of GREA, is pleased to announce the sale of a mixed-use portfolio of properties in the Washington Square West and Rittenhouse Square neighborhoods of Philadelphia.
  • Washington Square West is also the home of Thomas Jefferson University Hospital and Pennsylvania Hospital, both major employers in the City of Philadelphia.
  • The portfolio includes a unit mix of one, two, and three bedroom apartments as well as commercial units.
  • Based in Philadelphia, Pennsylvania, Rittenhouse Realty Advisors, a member of GREA, is a real estate advisory firm with an extensive focus in the brokerage of multi-family communities throughout the United States.

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Medical Devices, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Cardiology, FDA, Artery, Hank, University of Michigan, Population, POWER, Lithotripsy, Interventional cardiology, Industry, Generalized arterial calcification of infancy, Patient, CEO, State university system, BS, MBA, Technology, IVL, Royal Perth Hospital, AVS, Pennsylvania Hospital, Board of directors, Hillrom, PULSE, Dominican Republic, Pulse, Calcium, Board, Moyamoya disease, Elective surgery, Boston Scientific, Virginia Tech, Leg, University, Pharmaceutical industry, Medical imaging

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.